Barclays Starts Moderna, Inc. (MRNA) Neutral as Biotech Outlook Improves

We recently published an article titled 10 Best Long Term Healthcare Stocks to Buy.

On January 28, Barclays assumed coverage of Moderna, Inc. (NASDAQ:MRNA) with an Equal Weight rating and a $25 price target as part of a broader biotechnology coverage expansion. The firm expressed a constructive view on the sector heading into 2026, citing undervaluation, expected M&A activity, and improving industry fundamentals as supportive factors.

During Moderna’s third-quarter 2025 earnings call, the company reported revenue of approximately $1.0 billion, driven primarily by sales of its approved vaccines, including Spikevax, mNEXSPIKE, and mRESVIA. Moderna, Inc. (NASDAQ:MRNA) ended the quarter with $6.6 billion in cash and investments and guided to a year-end balance of $6.5 billion to $7.0 billion. The company emphasized disciplined capital management while continuing to fund pipeline development across multiple therapeutic areas.

Moderna, Inc. (NASDAQ:MRNA) was founded in September 2010 and is headquartered in Cambridge, Massachusetts. The company focuses on developing medicines using messenger RNA technology. Moderna is second on the list of 10 best long term healthcare stocks to buy.

While we acknowledge the potential of MRNA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRNA and that has a 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 8 Up and Coming Streaming Companies and Services and 9 High Growth Canadian Stocks to Buy

Disclosure: None.